© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Customized cell therapy plus Imbruvica leads to high response rate.
Venclexta plus Gazyva reduces risk of disease progression or death.
Here’s a list of approved drugs to treat leukemia including acute lymphocytic or lymphoblastic leukemia (ALL), chronic lymphocytic le...
INVAC-1 vaccine targets the telomerase enzyme involved in cancer cell growth.
Duvelisib granted regular approval for chronic lymphocytic leukemia and accelerated approval for follicular lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
